Search research articles
Contact Us
Filters
Showing results (41-50 of 63) with videos related to
Page
of 7
Sort By:
Cancer Research
|
October 1, 1994
Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185
S A Eccles, W J Court, G A Box, et al.
Gut
|
February 1, 1990
Gastric enterochromaffin-like (ECL) cells in hypergastrinaemic duodenal ulcer disease
M Coupe, H Rees, C J Springer, et al.
Anti-Cancer Drug Design
|
December 1, 1996
Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT)
C J Springer, V Bavetsias, A L Jackman, et al.
Regulatory Peptides
|
March 5, 1990
Do normal plasma neurotensin concentrations increase ileal output?
A D MacKay, H W Jones, A Gough, et al.
British Journal of Cancer
|
December 1, 1988
A cytotoxic agent can be generated selectively at cancer sites
K D Bagshawe, C J Springer, F Searle, et al.
Journal of Medicinal Chemistry
|
December 19, 1998
Self-immolative nitrogen mustard prodrugs for suicide gene therapy
D Niculescu-Duvaz, I Niculescu-Duvaz, F Friedlos, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1997
Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial
J Martin, S M Stribbling, G K Poon, et al.
Biochemical Society Transactions
|
November 1, 1995
Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour disease
D C Blakey, P J Burke, D H Davies, et al.
Journal of Medicinal Chemistry
|
December 22, 1995
Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT)
C J Springer, R Dowell, P J Burke, et al.
Cancer Research
|
August 27, 1999
Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent
R B Pedley, S K Sharma, G M Boxer, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 63) with videos related to
Sort By:
Page
of 7
Cancer Research
|
October 1, 1994
Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185
S A Eccles, W J Court, G A Box, et al.
Gut
|
February 1, 1990
Gastric enterochromaffin-like (ECL) cells in hypergastrinaemic duodenal ulcer disease
M Coupe, H Rees, C J Springer, et al.
Anti-Cancer Drug Design
|
December 1, 1996
Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT)
C J Springer, V Bavetsias, A L Jackman, et al.
Regulatory Peptides
|
March 5, 1990
Do normal plasma neurotensin concentrations increase ileal output?
A D MacKay, H W Jones, A Gough, et al.
British Journal of Cancer
|
December 1, 1988
A cytotoxic agent can be generated selectively at cancer sites
K D Bagshawe, C J Springer, F Searle, et al.
Journal of Medicinal Chemistry
|
December 19, 1998
Self-immolative nitrogen mustard prodrugs for suicide gene therapy
D Niculescu-Duvaz, I Niculescu-Duvaz, F Friedlos, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1997
Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial
J Martin, S M Stribbling, G K Poon, et al.
Biochemical Society Transactions
|
November 1, 1995
Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour disease
D C Blakey, P J Burke, D H Davies, et al.
Journal of Medicinal Chemistry
|
December 22, 1995
Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT)
C J Springer, R Dowell, P J Burke, et al.
Cancer Research
|
August 27, 1999
Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent
R B Pedley, S K Sharma, G M Boxer, et al.
Page
of 7